Literature DB >> 11389494

Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea.

H J Cheong1, C W Yoo, J W Sohn, W J Kim, M J Kim, S C Park.   

Abstract

Quinolone-resistant Escherichia coli (QREC) strains are being isolated with increasing frequency. From 1993 to 1998, 40 cases of QREC bacteremia were observed in a teaching hospital; 25 episodes (63.5%) were community-acquired. The incidence of QREC bacteremia increased steadily, from 6.7% to 24.6% during 5 years, and correlated with the significantly increased use of fluoroquinolones (P = .003, r = 0.98). When the 40 QREC bacteremic patients were compared with 80 patients with bacteremia due to quinolone-susceptible E. coli, prior fluoroquinolone use was the only independent risk factor for QREC bacteremia (P = .001). A high APACHE II score was the only independent risk factor for death. The rate of multidrug resistance of QREC was much higher (60%) than that of quinolone-susceptible isolates (13.8%). Pulsed-field gel electrophoresis patterns of these isolates were diverse. Therefore, the isolates revealed little evidence of clonal spread and may have emerged in direct response to the selective pressure exerted by prior fluoroquinolone use.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389494     DOI: 10.1086/320873

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

1.  The clinical impact of fluoroquinolone resistance in patients with E coli bacteremia.

Authors:  Bernard C Camins; Jonas Marschall; Shannon R DeVader; Dawn E Maker; Matthew W Hoffman; Victoria J Fraser
Journal:  J Hosp Med       Date:  2011 Jul-Aug       Impact factor: 2.960

Review 2.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

3.  Efficacy of rifaximin compared with ciprofloxacin for the treatment of acute infectious diarrhea: a randomized controlled multicenter study.

Authors:  Kyoung Sup Hong; You Sun Kim; Dong Soo Han; Chang Hwan Choi; Byung-Ik Jang; Young-Sook Park; Kang-Moon Lee; Soo Teik Lee; Hyun-Soo Kim; Joo Sung Kim
Journal:  Gut Liver       Date:  2010-09-24       Impact factor: 4.519

Review 4.  Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions.

Authors:  Rachel M Greenblatt; Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-21       Impact factor: 3.254

5.  Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: a clinical study.

Authors:  Ismaël Mohammedi; Dominique Ploin; Serge Duperret; François Chapuis; Paul Petit
Journal:  Intensive Care Med       Date:  2003-05-27       Impact factor: 17.440

6.  Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli.

Authors:  K Huotari; E Tarkka; V Valtonen; E Kolho
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-18       Impact factor: 3.267

Review 7.  Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance.

Authors:  E Montassier; E Batard; T Gastinne; G Potel; M F de La Cochetière
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-25       Impact factor: 3.267

8.  The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported.

Authors:  Maureen K Bolon; Sharon B Wright; Howard S Gold; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

9.  Isolation and molecular characterization of nalidixic acid-resistant extraintestinal pathogenic Escherichia coli from retail chicken products.

Authors:  James R Johnson; Andrew C Murray; Abby Gajewski; Maureen Sullivan; Paula Snippes; Michael A Kuskowski; Kirk E Smith
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  Antimicrobial-resistant invasive Escherichia coli, Spain.

Authors:  Jesús Oteo; Edurne Lázaro; Francisco J de Abajo; Fernando Baquero; José Campos
Journal:  Emerg Infect Dis       Date:  2005-04       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.